RemeGen Valuation

Q: What is the Fair Price of REGM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

REGM.F ($1.5) is trading below our estimate of [[fair value]] ($6.41)

Is REGM.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REGM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REGM.F ($1.5) is trading below our estimate of fair value ($6.41)

Significantly Below Fair Value: REGM.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGM.F?

Key metric: As REGM.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for REGM.F. This is calculated by dividing REGM.F's market cap by their current revenue.
What is REGM.F's PS Ratio?
PS Ratio	5.6x
Sales	CN¥1.52b
Market Cap	CN¥15.16b

REGM.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11x
Enterprise Value/EBITDA	-12.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does REGM.F's PS Ratio compare to its peers?

The above table shows the PS ratio for REGM.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	21.1x
MYGN Myriad Genetics	1.7x	7.2%	US$1.4b
KYMR Kymera Therapeutics	34.8x	16.2%	US$2.9b
NTLA Intellia Therapeutics	35x	67.2%	US$1.5b
VCEL Vericel	12.8x	21.1%	US$2.9b
REGM.F RemeGen	5.6x	25.9%	US$16.3b

Price-To-Sales vs Peers: REGM.F is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (21.1x).

Price to Sales Ratio vs Industry

How does REGM.F's PS Ratio compare vs other companies in the US Biotechs Industry?

128 Companies	Price / Sales	Estimated Growth	Market Cap
GILD Gilead Sciences	4x	2.4%	US$112.40b
BIIB Biogen	2.4x	1.3%	US$23.01b
MRNA Moderna	3.3x	6.8%	US$15.82b
INCY Incyte	3.5x	9.0%	US$13.82b

128 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: REGM.F is good value based on its Price-To-Sales Ratio (5.6x) compared to the US Biotechs industry average (9.4x).

Price to Sales Ratio vs Fair Ratio

What is REGM.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGM.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate REGM.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

6.1%

14.8%